Additional extension term for distribution of human serum albumin.

No definition available.

Name:	grfs_AdditionalExtensionTermForDistributionOfHumanSerumAlbumin
Namespace Prefix:	grfs_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The aggregate earnings before interest, taxes, depreciation, and amortization in subsidiary that the entity has committed to achieve during the period 2024 to 2028.

+ References

No definition available.

+ Details

Name:	grfs_AggregateEarningsBeforeInterestTaxesDepreciationAndAmortizationInSubsidiaryForSpecifiedPeriod
Namespace Prefix:	grfs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Number of Grains of Immunoglobulin agreed to receive.

+ References

No definition available.

+ Details

Name:	grfs_AgreementToReceiveNumberOfGrainsOfImmunoglobulin
Namespace Prefix:	grfs_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Amortisation period for voting proxy agreement.

+ References

No definition available.

+ Details

Name:	grfs_AmortisationPeriodForVotingProxyAgreement
Namespace Prefix:	grfs_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of indebtedness incurred by counterparty in connection to sale of subsidiary, representing the minimum exercise price of the share repurchase option.

+ References

No definition available.

+ Details

Name:	grfs_AmountOfIndebtednessIncurredByCounterpartyInConnectionToSaleOfSubsidiaryRepresentingMinimumExercisePriceOfShareRepurchaseOption
Namespace Prefix:	grfs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Represents the aggregate EBITDA amount committed by the entity under a contractual agreement for a specified period.

+ References

No definition available.

+ Details

Name:	grfs_CommittedEbitdaAmount
Namespace Prefix:	grfs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of consideration received on sale of subsidiaries.

+ References

No definition available.

+ Details

Name:	grfs_ConsiderationOnSaleOfSubsidiary
Namespace Prefix:	grfs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.

+ References

No definition available.

+ Details

Name:	grfs_DisclosureOfCommitmentsAndContingentLiabilitiesLineItems
Namespace Prefix:	grfs_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Income from amortization of voting proxy agreement.

+ References

No definition available.

+ Details

Name:	grfs_IncomeFromAmortizationOfVotingProxyAgreement
Namespace Prefix:	grfs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Increase (decrease) in loan amount

+ References

No definition available.

+ Details

Name:	grfs_IncreaseDecreaseInLoanAmount
Namespace Prefix:	grfs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Initial term for distribution of human serum albumin.

+ References

No definition available.

+ Details

Name:	grfs_InitialTermForDistributionOfHumanSerumAlbumin
Namespace Prefix:	grfs_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of loans and advances the entity has made to related parties.

+ References

No definition available.

+ Details

Name:	grfs_LoansAndAdvancesToRelatedParties
Namespace Prefix:	grfs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Number of plasma centers to be constructed.

+ References

No definition available.

+ Details

Name:	grfs_NumberOfPlasmaCentersToBeConstructed
Namespace Prefix:	grfs_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Penalties imposed against entity.

+ References

No definition available.

+ Details

Name:	grfs_PenaltiesImposedAgainstEntity
Namespace Prefix:	grfs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Percentage of distributable profit in subsidiary to be distributed for 2024 to 2028.

+ References

No definition available.

+ Details

Name:	grfs_PercentageOfDistributableProfitInSubsidiaryToBeDistributedForSpecifiedPeriod
Namespace Prefix:	grfs_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Period during which counterparty retains voting proxy in subsidiary.

+ References

No definition available.

+ Details

Name:	grfs_PeriodDuringWhichCounterpartyRetainsVotingProxyInSubsidiary
Namespace Prefix:	grfs_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Proportion of additional interest in subsidiary that entity has option to acquire.

+ References

No definition available.

+ Details

Name:	grfs_ProportionOfAdditionalInterestInSubsidiaryThatEntityHasOptionToAcquire
Namespace Prefix:	grfs_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of ownership interests in associate sold during the period.

+ References

No definition available.

+ Details

Name:	grfs_ProportionOfOwnershipInterestInAssociateSold
Namespace Prefix:	grfs_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The proportion of ownership interest in a subsidiary sold.

+ References

No definition available.

+ Details

Name:	grfs_ProportionOfOwnershipInterestInSubsidiarySold
Namespace Prefix:	grfs_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of cash compensation per ordinary share of target company to be paid by company upon finalization of the squeeze-out order, in accordance with the German Takeover Act.

+ References

No definition available.

+ Details

Name:	grfs_SqueezeOutCashCompensationPerShareAmount
Namespace Prefix:	grfs_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	duration

- Definition

Term of option to acquire additional ownership interests after end of management services

+ References

No definition available.

+ Details

Name:	grfs_TermOfOptionToAcquireAdditionalOwnershipInterestsAfterEndOfManagementServices
Namespace Prefix:	grfs_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Threshold period for exercise of options (call option and a put option for both shareholders which allows them to acquire or sell their entire stake to the counterparty)

+ References

No definition available.

+ Details

Name:	grfs_ThresholdPeriodForExerciseOfOptions
Namespace Prefix:	grfs_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The percentage of ownership to be maintained for achieving aggregate EBITDA for a specified period.

+ References

No definition available.

+ Details

Name:	grfs_ThresholdProportionOfOwnershipPercentageHeldForAggregateEarningsBeforeInterestTaxesDepreciationAndAmortizationInSubsidiaryForSpecifiedPeriod
Namespace Prefix:	grfs_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Value assigned to voting proxy agreement.

+ References

No definition available.

+ Details

Name:	grfs_ValueAssignedToVotingProxyAgreement
Namespace Prefix:	grfs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Volume of Canadian plasma needed to be collected annually.

+ References

No definition available.

+ Details

Name:	grfs_VolumeOfCanadianPlasmaNeedToCollectAnnually
Namespace Prefix:	grfs_
Data Type:	dtr-types:volumeItemType
Balance Type:	na
Period Type:	instant

- Definition

The adjustment to the basis (reference rate) used for calculation of the interest rate on borrowings. [Refer: Borrowings]

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IFRS
-Number 7
-IssueDate 2025-01-01
-Paragraph 7
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_7&doctype=Standard
-URIDate 2025-03-27

+ Details

Name:	ifrs-full_BorrowingsAdjustmentToInterestRateBasis
Namespace Prefix:	ifrs-full_
Data Type:	dtr-2022:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

The amount of capital commitments for which the entity has entered into a contract. [Refer: Capital commitments]

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Note Expiry date 2027-01-01
-Name IAS
-Number 1
-IssueDate 2025-01-01
-Paragraph 112
-Subparagraph c
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_112_c&doctype=Standard
-URIDate 2025-03-27

+ Details

Name:	ifrs-full_ContractualCapitalCommitments
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The proportion of ownership interest in a joint venture attributable to the entity. [Refer: Total for all joint ventures [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 27
-IssueDate 2025-01-01
-Paragraph 17
-Subparagraph b
-Clause iii
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_17_b_iii&doctype=Standard
-URIDate 2025-03-27

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 27
-IssueDate 2025-01-01
-Paragraph 16
-Subparagraph b
-Clause iii
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_16_b_iii&doctype=Standard
-URIDate 2025-03-27

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2025-01-01
-Paragraph 21
-Subparagraph a
-Clause iv
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_21_a_iv&doctype=Standard
-URIDate 2025-03-27

+ Details

Name:	ifrs-full_ProportionOfOwnershipInterestInJointVenture
Namespace Prefix:	ifrs-full_
Data Type:	dtr-2022:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Total for all subsidiaries [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 27
-IssueDate 2025-01-01
-Paragraph 17
-Subparagraph b
-Clause iii
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_17_b_iii&doctype=Standard
-URIDate 2025-03-27

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 27
-IssueDate 2025-01-01
-Paragraph 16
-Subparagraph b
-Clause iii
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_16_b_iii&doctype=Standard
-URIDate 2025-03-27

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2025-01-01
-Paragraph 19B
-Subparagraph c
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_19B_c&doctype=Standard
-URIDate 2025-03-27

+ Details

Name:	ifrs-full_ProportionOfOwnershipInterestInSubsidiary
Namespace Prefix:	ifrs-full_
Data Type:	dtr-2022:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The proportion of ownership interests in a subsidiary held by non-controlling interests. [Refer: Total for all subsidiaries [member]; Non-controlling interests]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2025-01-01
-Paragraph 12
-Subparagraph c
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_12_c&doctype=Standard
-URIDate 2025-03-27

+ Details

Name:	ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests
Namespace Prefix:	ifrs-full_
Data Type:	dtr-2022:percentItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	ifrs-full_SignificantInvestmentsInSubsidiariesAxis=grfs_PlasmavitaHealthcareGmbhMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_SignificantInvestmentsInSubsidiariesAxis=grfs_GrifolsDiagnosticSolutionsInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_SignificantInvestmentsInSubsidiariesAxis=grfs_BiotestAgMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=grfs_SqueezeOutProceedingsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_SignificantInvestmentsInAssociatesAxis=grfs_ShanghaiRaasBloodProductsCo.LtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_CategoriesOfRelatedPartiesAxis=grfs_ScrantonPlasmaBVMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_SignificantInvestmentsInSubsidiariesAxis=grfs_BpcPlasmaIncAndHaemaAgMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_ItemsOfContingentLiabilitiesAxis=grfs_ExecutiveCommitteeOfCnmvMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_TypesOfInterestRatesAxis=grfs_EuriborMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_CounterpartiesAxis=grfs_CanadianBloodServicesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_CounterpartiesAxis=grfs_HaierGroupCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_JointVenturesAxis=grfs_GrifolsEgyptMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=grfs_NationalServiceProjectsOrganizationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Other Commitments with Third Parties and Other Contingent Liabilities - Summary (Details) € / shares in Units, € in Millions, $ in Millions						2 Months Ended	12 Months Ended
	Feb. 10, 2026 € / shares	Feb. 14, 2025	Jul. 29, 2021 item	Dec. 28, 2018 USD ($)	Nov. 22, 2017	Oct. 31, 2025	Dec. 31, 2025 EUR (€)	Dec. 31, 2024 USD ($)	Dec. 31, 2024 EUR (€)	Dec. 31, 2023 EUR (€)	Sep. 25, 2024 EUR (€)	Sep. 30, 2022 item l	Dec. 28, 2018 EUR (€)
Plasmavita Healthcare GmbH (Germany)
Disclosure of commitments and contingent liabilities [line items]
Proportion of ownership interest in subsidiary					50.00%
Proportion of ownership interests held by non-controlling interests					50.00%
Proportion of additional interest in subsidiary that entity has option to acquire					50.00%
Term of option to acquire additional ownership interests after end of management services					6 months
Grifols Diagnostic Solutions, Inc.
Disclosure of commitments and contingent liabilities [line items]
Proportion of ownership interest in subsidiary								55.00%	55.00%	55.00%
Proportion of ownership interests held by non-controlling interests								45.00%	45.00%
Committed EBITDA amount									€ 850
Biotest AG
Disclosure of commitments and contingent liabilities [line items]
Proportion of ownership interest in subsidiary		71.68%				80.40%
Proportion of ownership interests held by non-controlling interests							19.60%	29.80%	29.80%
Biotest AG \| Squeeze out proceedings
Disclosure of commitments and contingent liabilities [line items]
Proportion of ownership interest in subsidiary	100.00%
Squeeze out cash compensation, per share amount \| € / shares	€ 43
Shanghai RAAS Blood Products Co., Ltd.
Disclosure of commitments and contingent liabilities [line items]
Percentage of sales							20.00%	20.00%	20.00%
Initial term								10 years	10 years
Additional extension term								10 years	10 years
Scranton Plasma B V
Disclosure of commitments and contingent liabilities [line items]
Increase (decrease) in loan amount										€ 15
Loans to related parties				$ 95			€ 124		€ 132				€ 87
Scranton Plasma B V \| BPC Plasma, Inc and Haema, AG
Disclosure of commitments and contingent liabilities [line items]
Consideration on sale of Subsidiary \| $				$ 538
Amount of indebtedness incurred by counterparty in connection to sale of subsidiary, representing the minimum exercise price of share repurchase option													€ 425
Percentage of sale of interest				100.00%
Maximum \| EXECUTIVE COMMITTEE OF CNMV
Disclosure of commitments and contingent liabilities [line items]
Penalties imposed against entity											€ 1
Euribor \| Scranton Plasma B V
Disclosure of commitments and contingent liabilities [line items]
Adjustment to interest rate basis (as a percent)				2.00%									2.00%
Canadian Blood Services
Disclosure of commitments and contingent liabilities [line items]
Number of Million Grains of Immunoglobulin agreed to receive \| item												2,400,000
Volume of Canadian Plasma Need to Collect Annually \| l												600
Canadian Blood Services \| 2026
Disclosure of commitments and contingent liabilities [line items]
Contractual capital commitments							6
Canadian Blood Services \| 2027
Disclosure of commitments and contingent liabilities [line items]
Contractual capital commitments							31
Haier \| Shanghai RAAS Blood Products Co., Ltd. \| Grifols Diagnostic Solutions, Inc.
Disclosure of commitments and contingent liabilities [line items]
Aggregate EBITDA for 2024 to 2028 \| $								$ 850
Percentage of distributable profit to be distributed for 2024 to 2028									50.00%
Period during which counterparty retains voting proxy in subsidiary								10 years	10 years
Income from amortization of voting proxy agreement							€ 3	$ 2
Value assigned to voting proxy agreement									€ 10
Amortisation period for voting proxy agreement								3 years	3 years
Haier \| Minimum \| Shanghai RAAS Blood Products Co., Ltd. \| Grifols Diagnostic Solutions, Inc.
Disclosure of commitments and contingent liabilities [line items]
Threshold Proportion of Ownership Percentage Held For Aggregate Earnings Before Interest Taxes Depreciation And Amortization In Subsidiary For Specified Period								10.00%	10.00%
Grifols Egypt
Disclosure of commitments and contingent liabilities [line items]
Number of plasma centers to be constructed \| item			20
Percentage of ownership in joint venture			49.00%
Threshold period for exercise of options			10 years
Grifols Egypt \| National Service Projects Organization (NSPO)
Disclosure of commitments and contingent liabilities [line items]
Percentage of ownership in joint venture			51.00%